1. United Kingdom Stocks

  2. •

    Health technology

  3. •

    Pharmaceuticals: major
Eco Animal Health Group PLC

Eco Animal Health Group PLC

LLSE:EAH
95.50
GBX
0.00
(0.00%)
6.40BMarket Cap
Nov 19Next Earn
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
2026 Y
TTM
Revenue per Share
0.57
0.65
0.76
0.95
1.02
1.01
1.07
1.56
1.21
1.26
1.32
1.18
1.29
- -
Basic EPS, GAAP
0.04
0.07
0.1
0.16
0.14
0.11
0.06
0.11
-0.01
0.01
0.02
0.02
0.03
- -
Free Cash Flow per Basic Share
0.03
0.02
-0.07
0.06
0.1
0.04
0.02
0.16
-0.05
0.15
0.07
0.08
0.06
- -
Dividend per Share
0.05
0.04
0.06
0.07
0.09
0.15
0.12
0.01
0.04
0.03
0.04
0.02
0.04
- -
Book Value per Share
1.13
1.16
1.28
1.43
1.23
1.16
1.09
1.21
1.21
1.23
1.24
1.27
1.31
1.31
Tangible Book Value per Share
0.44
0.44
0.51
0.61
0.63
0.64
0.56
0.68
0.71
0.7
0.67
0.65
0.64
0.64
Basic Weighted Avg Shares
56
60
62
65
66
67
68
68
68
68
68
68
68
68
Sales/Revenue/Turnover
32
39
47
61
67
67
72
106
82
85
89
80
88
- -
Operating Margin (%)
12.05
13.32
15.41
20.24
20.57
14.96
8.51
18.42
4.29
5.8
4.68
4.2
6.53
- -
Depreciation Expense
3
3
3
3
4
2
1
2
2
2
3
3
3
- -
Net Income, GAAP
2
4
6
11
9
7
4
7
-1
1
1
2
2
- -
Effective Tax Rate (%)
16.35
9
12.92
10.8
16.04
12.29
10.72
18.05
150.76
30.38
32.48
34.3
32.74
- -
Profit Margin (%)
7.63
10.5
12.81
17.2
13.86
10.78
5.4
6.95
-0.83
1.18
1.17
2.12
2.5
- -
Working Capital
29
29
35
43
44
46
40
56
55
52
50
48
46
46
LT Debt
- -
- -
- -
- -
- -
1
1
1
2
4
3
3
4
4
Total Equity
73
76
85
98
86
83
79
95
94
96
93
95
96
96
Return on Invested Capital (%)
4.89
6.39
7.89
12.27
12.82
10.23
6.45
17.34
-0.74
3.49
2.41
2.9
3.97
- -
Return on Capital (%)
2.68
4.75
6.55
9.95
7.58
6.74
2.89
-1.01
-0.84
-0.63
0.61
1.06
1
- -
Return on Common Equity (%)
3.78
5.69
7.77
12.01
10.65
9.11
5.13
9.43
-0.84
1.22
1.26
1.99
2.54
- -

Capital Structure

GBP

•

in mil. unless spec.
Mar'25
Sep'26
Mar'26
ST Debt
1
1
1
LT Borrowings
- -
- -
- -
LT Finance Leases
3
4
4
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
67
67
67
Market Capitalization
36
64
64

Working Capital

GBP

•

in mil. unless spec.
Mar'25
Sep'26
Mar'26
Total Current Assets
70
61
64
Cash, Cash Equivalents & STI
25
19
25
Accounts Receivable, Net
25
24
22
Inventories
15
16
14
Total Current Liabilities
22
16
19
Payables & Accruals
- -
- -
- -
ST Debt
1
1
1
Deferred Revenue
- -
- -
- -

Growth Rates

GBP

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
1.5%
0.05%
0.78%
Free Cash Flow
-17.4%
-117.47%
-28.77%
Net Income, GAAP
-17.84%
-52.31%
29.89%
Sales/Revenue/Turnover
7.89%
-2.92%
9.96%
Total Cash Common Dividend
52.69%
100.74%
134.18%

Semi-annual Revenue

GBP

•

in mil. unless spec.

Year

H1
H2
FY
2024
- -
- -
89
2025
- -
- -
80
2026
- -
- -
88

Semi-annual Earnings Per Share

GBP

•

in mil. unless spec.

Year

H1
H2
FY
2024
- -
- -
0.02
2025
- -
- -
0.02
2026
- -
- -
0.03

Semi-annual Dividends Per Share

GBP

•

in mil. unless spec.

Year

H1
H2
FY
2024
- -
- -
0.04
2025
- -
- -
0.02
2026
- -
- -
0.04

Company Description

Company Profile APIChatGPT
CEO
David Charles Hallas
Full Time Employees
213
Sector
Health technology
Industry
Pharmaceuticals: major
Address
The Grange London LO United Kingdom N14 6BN
IPO Date
Sep 26, 1995
Website
ecoanimalhealth.com
Similar Companies
Eli Lilly and Company (NYSE:LLY)
Novo Nordisk A/S (NYSE:NVO)
Johnson & Johnson (NYSE:JNJ)
Pfizer, Inc. (NYSE:PFE)
Dr. Reddy's Laboratories Ltd. (NSE:DRREDDY)
Divi's Laboratories Limited (NSE:DIVISLAB)
Business
ECO Animal Health Group plc (EAH.L) develops, manufactures and commercialises treatments for livestock disease prevention and control. The company offers a portfolio of pharmaceutical products including Aivlosin, a pleuromutilin antibiotic for respiratory and enteric diseases in swine and poultry; Equimax and Equimax Tabs, broad-spectrum equine anthelmintics; and Ecomectin, an ivermectin pour-on for cattle parasite control; as well as Evap, an otic suspension for canine ear infections, and generic equivalents across veterinary categories. ECO operates primarily in the animal health segment, targeting livestock producers, veterinarians and pet owners with products focused on swine, poultry, cattle, equine and companion animals. Founded in 1972 and headquartered in London, United Kingdom, the company maintains manufacturing facilities in the UK and Denmark, with commercial operations spanning Europe, North America, Asia and Latin America through subsidiaries and distribution partnerships. In recent developments, ECO Animal Health Group reported steady revenue growth in fiscal 2025 driven by expanded Aivlosin sales in key markets and ongoing investment in R&D for novel antimicrobials, amid a strategic focus on sustainable animal health solutions without notable acquisitions, partnerships or reorganizations in the past 1-2 years.